OTCMKTS:CLXPF

Cybin News Headlines

$1.40
-0.05 (-3.45 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.30
Now: $1.40
$1.49
50-Day Range
$0.96
MA: $1.22
$1.48
52-Week Range
$0.49
Now: $1.40
$2.24
Volume492,319 shs
Average Volume439,984 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Cybin (OTCMKTS CLXPF) News Headlines Today

SourceHeadline
Psychedelics Could Play a Crucial Role in Your Mental Health Treatment - Baystreet.caPsychedelics Could Play a Crucial Role in Your Mental Health Treatment - Baystreet.ca
baystreet.ca - April 14 at 3:51 PM
Industry Leaders Look To Artificial Intelligence To Drive Advancements In Mental Healthcare - Baystreet.caIndustry Leaders Look To Artificial Intelligence To Drive Advancements In Mental Healthcare - Baystreet.ca
baystreet.ca - April 14 at 10:51 AM
Mainstream Mental Health is Quickly Embracing Psychedelic Drug Therapies - Baystreet.caMainstream Mental Health is Quickly Embracing Psychedelic Drug Therapies - Baystreet.ca
baystreet.ca - April 13 at 7:47 PM
Cybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug Applications - Business WireCybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug Applications - Business Wire
businesswire.com - April 13 at 7:47 PM
Cybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug ApplicationsCybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug Applications
finance.yahoo.com - April 13 at 9:46 AM
Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Completes Pre-Clinical Studies, Progresses Two Drug Candidates - StreetInsider.comCybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Completes Pre-Clinical Studies, Progresses Two Drug Candidates - StreetInsider.com
streetinsider.com - April 7 at 2:33 PM
Music May Play a Critical Role in Psychedelic Therapy Sessions - Baystreet.caMusic May Play a Critical Role in Psychedelic Therapy Sessions - Baystreet.ca
baystreet.ca - April 6 at 1:31 PM
With US FDA Support and Breakthroughs, Psilocybin a Step Closer to Legalization - Baystreet.caWith US FDA Support and Breakthroughs, Psilocybin a Step Closer to Legalization - Baystreet.ca
baystreet.ca - March 31 at 7:47 PM
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Appoints New Management Positions, Focused on Development and Clinical Operations - StreetInsider.comPsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Appoints New Management Positions, Focused on Development and Clinical Operations - StreetInsider.com
streetinsider.com - March 30 at 1:32 PM
Cybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United States and EuropeCybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United States and Europe
finance.yahoo.com - March 30 at 8:32 AM
Cybin Inc. (OTCMKTS:CLXPF) Short Interest Up 101.7% in MarchCybin Inc. (OTCMKTS:CLXPF) Short Interest Up 101.7% in March
americanbankingnews.com - March 29 at 5:42 PM
Mycology Interest on the Rise as Researchers Unearth More Benefits of Functional Mushroom Products - Baystreet.caMycology Interest on the Rise as Researchers Unearth More Benefits of Functional Mushroom Products - Baystreet.ca
baystreet.ca - March 27 at 7:49 PM
Psyched: Compass New Patents, Cure Extends DEA License, Andrew Yang Supports Psilocybin in NYC - Yahoo FinancePsyched: Compass' New Patents, Cure Extends DEA License, Andrew Yang Supports Psilocybin in NYC - Yahoo Finance
finance.yahoo.com - March 27 at 7:49 PM
NetworkNewsAudio – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Poised to Profit as Investor Interest in Psychedelic Therapeutics Market Increases - StreetInsider.comNetworkNewsAudio – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Poised to Profit as Investor Interest in Psychedelic Therapeutics Market Increases - StreetInsider.com
streetinsider.com - March 27 at 7:49 PM
Cybin Inc. (NEO: CYBN) in Prime Position as Interest in Psychedelic Medicine Surges - Yahoo FinanceCybin Inc. (NEO: CYBN) in Prime Position as Interest in Psychedelic Medicine Surges - Yahoo Finance
finance.yahoo.com - March 27 at 7:49 PM
Cybin Inc. (NEO: CYBN) at Forefront of Psychedelic Revolution - Yahoo FinanceCybin Inc. (NEO: CYBN) at Forefront of Psychedelic Revolution - Yahoo Finance
finance.yahoo.com - March 27 at 7:49 PM
Cybin Inc. (NEO: CYBN) at Forefront of Psychedelic RevolutionCybin Inc. (NEO: CYBN) at Forefront of Psychedelic Revolution
finance.yahoo.com - March 26 at 8:45 AM
Catalent Signs Drug Development Agreement with Cybin Inc for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)Catalent Signs Drug Development Agreement with Cybin Inc for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)
finance.yahoo.com - March 22 at 1:01 PM
Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)
finance.yahoo.com - March 22 at 8:01 AM
Cybin Progresses Two Psychedelic Investigational New Drug ("IND") Candidates and Announces Completion of Its 20th Pre-Clinical StudyCybin Progresses Two Psychedelic Investigational New Drug ("IND") Candidates and Announces Completion of Its 20th Pre-Clinical Study
finance.yahoo.com - March 17 at 8:34 AM
Cybin to Present at the Oppenheimer 31st Annual Healthcare ConferenceCybin to Present at the Oppenheimer 31st Annual Healthcare Conference
finance.yahoo.com - March 16 at 9:11 AM
With Recent Advancements, North America Is Expected To Dominate Psychedelic Drugs MarketWith Recent Advancements, North America Is Expected To Dominate Psychedelic Drugs Market
finanznachrichten.de - March 9 at 1:01 PM
Cybin Announces API Synthesis and Optimization of Multiple Tryptamine Derivatives and Nomination of Two Deuterated Candidates for Full IND Enabling Studies Based on Second Milestone Achievement Pursuant to the Adelia AcquisitionCybin Announces API Synthesis and Optimization of Multiple Tryptamine Derivatives and Nomination of Two Deuterated Candidates for Full IND Enabling Studies Based on Second Milestone Achievement Pursuant to the Adelia Acquisition
finance.yahoo.com - March 9 at 1:01 PM
Cybin Inc. Shares Commence Trading on the OTCQB Venture Market on March 8, 2021Cybin Inc. Shares Commence Trading on the OTCQB Venture Market on March 8, 2021
finance.yahoo.com - March 8 at 8:37 AM
Cybin Inc. Announces Uplisting to OTCQB Venture MarketCybin Inc. Announces Uplisting to OTCQB Venture Market
finance.yahoo.com - March 3 at 8:37 AM
Global Behavioral Health Market Where Psychedelics Have Shown Tremendous Potential Could Hit $240 Billion By 2026 - MarketWatchGlobal Behavioral Health Market Where Psychedelics Have Shown Tremendous Potential Could Hit $240 Billion By 2026 - MarketWatch
marketwatch.com - March 2 at 2:16 PM
Innovators Identify Crucial Advancements to Uncover Medical Breakthroughs From PsychedelicsInnovators Identify Crucial Advancements to Uncover Medical Breakthroughs From Psychedelics
baystreet.ca - March 2 at 9:09 AM
Medical Community Sees Cause For High Hopes As Psychedelics Emerge As Potential Treatment For TraumaMedical Community Sees Cause For High Hopes As Psychedelics Emerge As Potential Treatment For Trauma
baystreet.ca - February 17 at 9:39 AM
Cybin Inc. Releases Financial Highlights and Provides Business UpdateCybin Inc. Releases Financial Highlights and Provides Business Update
finance.yahoo.com - February 16 at 11:29 PM
Cybin to Provide Business Update on February 17, 2021 Conference CallCybin to Provide Business Update on February 17, 2021 Conference Call
finance.yahoo.com - February 11 at 12:50 PM
Cybin Announces Closing of Upsized Bought Deal OfferingCybin Announces Closing of Upsized Bought Deal Offering
finance.yahoo.com - February 4 at 3:29 PM
Cybin Included in First Psychedelic Exchange Traded FundCybin Included in First Psychedelic Exchange Traded Fund
finance.yahoo.com - January 27 at 3:01 PM
Cybin Inc. (CLXPF)Cybin Inc. (CLXPF)
in.finance.yahoo.com - January 19 at 4:02 PM
CYBIN Announces Upsize to Previously Announced Bought Deal OfferingCYBIN Announces Upsize to Previously Announced Bought Deal Offering
finance.yahoo.com - January 19 at 4:02 PM
Cybin Announces CDN$20 Million Bought Deal OfferingCybin Announces CDN$20 Million Bought Deal Offering
finance.yahoo.com - January 18 at 9:47 AM
IIROC Trading Halt - CYBNIIROC Trading Halt - CYBN
finance.yahoo.com - January 15 at 1:43 PM
IIROC Trade Resumption - CYBNIIROC Trade Resumption - CYBN
finance.yahoo.com - January 15 at 1:43 PM
New Psychedelics Studies Could Shed Light on Treatment for Obesity EpidemicNew Psychedelics Studies Could Shed Light on Treatment for Obesity Epidemic
baystreet.ca - January 12 at 1:34 PM
Cybin Announces API Synthesis of Multiple Tryptamine Derivatives Based on the First Milestone Achievement Pursuant to the Adelia AcquisitionCybin Announces API Synthesis of Multiple Tryptamine Derivatives Based on the First Milestone Achievement Pursuant to the Adelia Acquisition
finance.yahoo.com - January 11 at 10:31 PM
Emerging Markets Report: A Time to GrowEmerging Markets Report: A Time to Grow
finance.yahoo.com - January 11 at 5:20 PM
KCSA Strategic Communications to Host Inaugural KCSA Psychedelics Investor Conference on January 26-27, 2021KCSA Strategic Communications to Host Inaugural KCSA Psychedelics Investor Conference on January 26-27, 2021
finance.yahoo.com - January 11 at 5:20 PM
Psychedelics Could Help Nearly 700 Million People Struggling with Mental Health IssuesPsychedelics Could Help Nearly 700 Million People Struggling with Mental Health Issues
baystreet.ca - January 11 at 12:18 PM
Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic TherapeuticsCybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic Therapeutics
finance.yahoo.com - January 11 at 12:17 PM
Psychedelics Legalization Efforts Quickly Gaining MomentumPsychedelics Legalization Efforts Quickly Gaining Momentum
baystreet.ca - January 7 at 9:02 AM
North America Psychedelic Drugs Market Could Exceed $6.8 Billion By 2027North America Psychedelic Drugs Market Could Exceed $6.8 Billion By 2027
finanznachrichten.de - January 6 at 5:52 PM
CYBIN Provides Update on Patent Filings & Development of Therapeutics ProgramCYBIN Provides Update on Patent Filings & Development of Therapeutics Program
finance.yahoo.com - January 6 at 12:49 PM
Psychedelic Companies Launch Digital Therapeutics Platforms To Accelerate And Improve Medicinal Psychedelic ResearchPsychedelic Companies Launch Digital Therapeutics Platforms To Accelerate And Improve Medicinal Psychedelic Research
baystreet.ca - January 6 at 7:47 AM
News for Cybin Inc Registered ShsNews for Cybin Inc Registered Shs
markets.businessinsider.com - December 24 at 7:36 AM
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.